- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07491224
Evaluation of Vaginal Laxity and Bladder Neck Descent in Parous Women Using 2D and 3D Transperineal Ultrasound (VLBNDUS)
March 19, 2026 updated by: Ola Abd El Hares Mahros Ali, Assiut University
This study aims to evaluate vaginal laxity and bladder neck descent in women who have given birth, using non-invasive 2D and 3D transperineal ultrasound.
Participants will complete a short questionnaire about pelvic floor symptoms and undergo a pelvic examination.
The ultrasound will measure bladder neck position, levator hiatus dimensions, and related pelvic floor structures at rest and during straining.
The study will compare findings between women with previous vaginal deliveries and those who had cesarean sections.
Participation is voluntary, and all procedures are safe, non-invasive, and similar to routine clinical practice.
The results will help better understand pelvic floor changes after childbirth and may improve the management of pelvic floor disorders.
Study Overview
Status
Not yet recruiting
Detailed Description
Pelvic floor dysfunction is a common condition affecting women after childbirth, often resulting in vaginal laxity, bladder neck descent, and related pelvic floor symptoms such as urinary incontinence and sexual dysfunction.
This observational cross-sectional study will assess 185 parous women, aged 18 years or older, using both 2D and 3D transperineal ultrasound.
Participants will complete the Pelvic Floor Distress Inventory-20 questionnaire and undergo a pelvic examination using the POP-Q system after bladder emptying.
Ultrasound measurements will include bladder neck height, retrovesical angle, levator hiatal dimensions, levator ani muscle integrity, and other related parameters at rest and during Valsalva maneuver.
Women will be categorized based on mode of delivery (vaginal vs cesarean) and results will be analyzed to determine correlations between pelvic floor anatomy and symptom severity.
The study aims to provide a comprehensive understanding of pelvic floor alterations in parous women, which may inform clinical assessment and management strategies for pelvic floor dysfunction.
Study Type
Observational
Enrollment (Estimated)
185
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ola Abd El Hares Mahros Ali resistant Obstetrics & Gynecology Department Assiut University
- Phone Number: 01158002972
- Email: drola6181@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The study population consists of parous women attending the Women's Health Hospital, Urogynecology and Advanced Ultrasound units.
Participants will include women with at least one vaginal delivery or only cesarean deliveries, aged 18 years or older.
They will be recruited to assess pelvic floor function and anatomical changes using 2D and 3D transperineal ultrasound.
Description
Inclusion Criteria:
- Parous women aged 18 years or older
- Willing to provide informed consent
- Able to complete the Pelvic Floor Distress Inventory-20 questionnaire
- Undergo 2D and 3D transperineal ultrasound and POP-Q examination
Exclusion Criteria:
- Pregnant women
- History of previous prolapse surgery
- Patients with neurological disorders affecting pelvic floor function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Vaginal Delivery (VD)
Women who have had at least one vaginal delivery.
Participants will undergo pelvic floor evaluation including 2D and 3D transperineal ultrasound, complete the Pelvic Floor Distress Inventory-20 questionnaire, and undergo POP-Q clinical examination.
No therapeutic interventions are assigned.
|
|
Cesarean Section (CS)
Women who have had only cesarean deliveries.
Participants will undergo pelvic floor evaluation including 2D and 3D transperineal ultrasound, complete the Pelvic Floor Distress Inventory-20 questionnaire, and undergo POP-Q clinical examination.
No therapeutic interventions are assigned.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Levator Hiatal Area
Time Frame: Measured once during ultrasound assessment after bladder emptying
|
Levator hiatal area will be measured using 2D and 3D transperineal ultrasound in the midsagittal plane.
Measurements will be taken at rest and during maximal Valsalva maneuver to assess pelvic floor anatomy in parous women and compare between vaginal delivery and cesarean section groups.
|
Measured once during ultrasound assessment after bladder emptying
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2026
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
April 1, 2027
Study Registration Dates
First Submitted
March 19, 2026
First Submitted That Met QC Criteria
March 19, 2026
First Posted (Actual)
March 24, 2026
Study Record Updates
Last Update Posted (Actual)
March 24, 2026
Last Update Submitted That Met QC Criteria
March 19, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- VaginalLaxity_US_2026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Floor Dysfunction; Vaginal Laxity; Bladder Neck Descent in Parous Women
-
National Taiwan University HospitalCompletedBladder Outlet Obstruction and Detrusor Underactivity in Women With Severe Cystocele
-
Fudan UniversityCompletedLower Urinary Tract Symptoms | Cervical Cancer | Urinary Retention | Pelvic Floor Muscle Weakness | Postoperative Bladder Dysfunction | Recovery of Bladder Function | Improvement in Pelvic Floor Muscle Strength | Enhancement of Quality of LifeChina